[CAS NO. 1383450-81-4] Rilematovir
PRODUCTS SPECIFICATIONS [1383450-81-4]
DESCRIPTION [1383450-81-4]
Overview
| MDL | MFCD30489307 |
|---|---|
| Molecular Weight | 500.92 |
| Molecular Formula | C21H20ClF3N4O3S |
| SMILES | O=C(N1CC(F)(F)F)N(CC(N2CCCS(=O)(C)=O)=CC3=C2C=CC(Cl)=C3)C4=C1C=CN=C4 |
2 Publications Citing Use of MCE
Summary
Rilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus (RSV) research.
IC50 & Target
Fusion protein [1]
In Vitro
Rilematovir is a small-molecule respiratory syncytial virus (RSV) fusion inhibitor currently under clinical evaluation in infants hospitalized for RSV infection. Rilematovir binds to RSV F protein in its prefusion conformation. Rilematovir displays very potent antiviral activity and low cytotoxicity. In addition to its activity against the RSV A2 strain, Rilematovir is also highly active against a number of RSV strains from both A and B subtypes. The EC 50 in an RSV infection assay using HeLa cells is 460 pM [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Oral treatment of neonatal lambs with Rilematovir, or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04583280 | Janssen Research & Development, LLC |
Respiratory Tract Infections
|
September 6, 2021 | Phase 3 |
| NCT04332523 | Janssen Research & Development, LLC |
Hepatic Impairment
|
August 17, 2020 | Phase 1 |
| NCT04978337 | Janssen Research & Development, LLC |
Respiratory Syncytial Virus
|
November 17, 2021 | Phase 2 |
| NCT04090086 | Janssen Research & Development, LLC |
Healthy
|
September 16, 2019 | Phase 1 |
| NCT03002779 | Janssen Research & Development, LLC |
Healthy
|
January 26, 2017 | Phase 1 |
| NCT05155007 | Janssen Research & Development, LLC |
Healthy
|
December 10, 2021 | Phase 1 |
| NCT03379675 | Janssen Research & Development, LLC |
Respiratory Syncytial Virus Infections
|
February 6, 2018 | Phase 2 |
| NCT02387606 | Janssen Sciences Ireland UC |
Respiratory Syncytial Virus Infections
|
May 7, 2015 | Phase 2 |
| NCT02398591 | Janssen Sciences Ireland UC |
Healthy
|
April 1, 2015 | Phase 1 |
| NCT02729467 | Janssen Research & Development, LLC |
Healthy
|
March 2016 | Phase 1 |
| NCT04221412 | Janssen Sciences Ireland UC |
Respiratory Syncytial Virus
|
||
| NCT02593851 | Janssen Sciences Ireland UC |
Respiratory Syncytial Virus Infections|Virus Diseases
|
December 4, 2015 | Phase 1 |
| NCT02945007 | Janssen Research & Development, LLC |
Healthy
|
November 8, 2016 | Phase 1 |
| NCT04056611 | Janssen Sciences Ireland UC |
Respiratory Syncytial Virus Infections
|
December 26, 2019 | Phase 2 |
| NCT04068792 | Janssen Research & Development, LLC |
Respiratory Syncytial Viruses
|
October 10, 2019 | Phase 2 |
| NCT03696459 | Janssen Research & Development, LLC |
Healthy
|
October 2, 2018 | Phase 1 |
| NCT03656510 | Janssen Research & Development, LLC |
Respiratory Syncytial Virus Infections
|
November 29, 2018 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 65 mg/mL ( 129.76 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.9963 mL | 9.9816 mL | 19.9633 mL |
| 5 mM | 0.3993 mL | 1.9963 mL | 3.9927 mL |
| 10 mM | 0.1996 mL | 0.9982 mL | 1.9963 mL |